Clinical Trial Update: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating toripalimab plus gemox as first-line therapy for intrahepatic cholangiocarcinoma is reported as ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN